Azurrx Biopharma Inc (AZRX) Stock Price, Quote, News and Overview
NASDAQ:AZRX - Nasdaq -
AZRX Quote, Performance and Key Statistics
3.45
+0.07 (+2.07%)
The current stock price of AZRX is 3.45 null. In the past month the price decreased by -40.65%. In the past year, price decreased by -52.21%.
AZRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.74 | 339.94B | ||
| AMGN | AMGEN INC | 14.22 | 158.77B | ||
| GILD | GILEAD SCIENCES INC | 14.17 | 136.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.81 | 61.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.07B | ||
| ARGX | ARGENX SE - ADR | 97.43 | 34.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.14B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.39 | 27.09B | ||
| NTRA | NATERA INC | N/A | 21.91B | ||
| BIIB | BIOGEN INC | 8.48 | 19.67B | ||
| INSM | INSMED INC | N/A | 18.63B |
Related stock screener links
About AZRX
Company Profile
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Delray Beach, Florida and currently employs 12 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company focused on developing its pipeline of gut-restricted GI clinical drug candidates, including MS1819 and niclosamide. Its therapeutic product pipeline consists of three clinical-stage programs. The Company’s lead drug candidate is MS1819. The company is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). The company is an an oral non-systemic biologic capsule. MS1819 is in two Phase II CF clinical trials. The company is a pro-inflammatory pathway inhibitor, is a prescription small molecule drug that has been safely used on millions of patients.
Company Info
Azurrx Biopharma Inc
1615 SOUTH CONGRESS AVENUE, SUITE 103
Delray Beach FLORIDA 33445 US
CEO: James Sapirstein
Employees: 12
Phone: 16466997855.0
Azurrx Biopharma Inc / AZRX FAQ
What is the stock price of Azurrx Biopharma Inc today?
The current stock price of AZRX is 3.45 null. The price increased by 2.07% in the last trading session.
What is the ticker symbol for Azurrx Biopharma Inc stock?
The exchange symbol of Azurrx Biopharma Inc is AZRX and it is listed on the Nasdaq exchange.
On which exchange is AZRX stock listed?
AZRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Azurrx Biopharma Inc stock?
4 analysts have analysed AZRX and the average price target is 3.4 null. This implies a price decrease of -1.45% is expected in the next year compared to the current price of 3.45. Check the Azurrx Biopharma Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Azurrx Biopharma Inc worth?
Azurrx Biopharma Inc (AZRX) has a market capitalization of 32.17M null. This makes AZRX a Nano Cap stock.
How many employees does Azurrx Biopharma Inc have?
Azurrx Biopharma Inc (AZRX) currently has 12 employees.
What are the support and resistance levels for Azurrx Biopharma Inc (AZRX) stock?
Azurrx Biopharma Inc (AZRX) has a resistance level at 5.13. Check the full technical report for a detailed analysis of AZRX support and resistance levels.
Should I buy Azurrx Biopharma Inc (AZRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AZRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AZRX, evaluating the profitability, health, valuation and growth aspects
- Azurrx Biopharma Inc (AZRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Azurrx Biopharma Inc (AZRX) Sales and EPS estimates to see what analysts future expectations are.
- Azurrx Biopharma Inc (AZRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Azurrx Biopharma Inc (AZRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- Azurrx Biopharma Inc (AZRX) Stock Chart to make your own analysis
- Azurrx Biopharma Inc (AZRX) Latest news and press-releases to stay up to date.
Does Azurrx Biopharma Inc (AZRX) stock pay dividends?
AZRX does not pay a dividend.
What is the Price/Earnings (PE) ratio of Azurrx Biopharma Inc (AZRX)?
Azurrx Biopharma Inc (AZRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.78).
AZRX Technical Analysis
AZRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AZRX. Both the profitability and financial health of AZRX have multiple concerns.
AZRX Financial Highlights
Over the last trailing twelve months AZRX reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS decreased by -32.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -288.01% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AZRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 90% to AZRX. The Buy consensus is the average rating of analysts ratings from 4 analysts.